Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration
Immunome got permission to test a new cancer medicine on people. This shows the FDA thinks the drug idea is safe enough to try.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.